Rabisin® / Raboral V-RG®
Rabisin® is used for the active immunisation of dogs and cats to reduce mortality and clinical signs due to rabies infection.
Search
BTV PUR®
Active immunisation of sheep to prevent viraemia and to reduce clinical signs caused by bluetongue virus serotypes 1, 2, 4 and/or 8 (combination of maximum 2 serotypes).
vaxxitek® hvt + ibd + nd
Bursal Disease-Marek's disease-Newcastle disease vaccine, serotype 3, live Marek's disease vector; the vaccine includes a diluent
Prascend
Symptomatic treatment of clinical signs associated with pituitary pars intermedia dysfunction (PPID; also known as equine Cushing’s disease).
Vetera
For vaccination of healthy horses as an aid in the prevention of diseases caused by the included antigens (US and Canada only).
FRONTLINE
indicated for the treatment and prevention of fleas, ticks and chewing lice in dogs and cats, and aids in the control of sarcoptic mange in dogs.
NexGard
Delivered in a highly palatable beef-flavoured chew that kills adult fleas and is indicated for the treatment and prevention of flea infestations and the treatment and control of tick infestations in dogs and puppies.
NexGard Spectra
Prevents heartworm disease and treats and controls hookworm, roundworm, whipworm, and lungworm infestations in dogs and puppies.
Heartgard Plus
Prevents canine heartworm disease by eliminating the tissue stage of heartworm larvae for a month after infection, also treatment and control of roundworms and hookworms.
GastroGard® / UlcerGard®
For treatment and prevention of gastric ulcers and prevention of recurrence of gastric ulcers in horses and foals four weeks of age and older.
Eqvalan® / Zimecterin® / Eqvalan®GoldEqvalan®Duo / Zimecteri
For treatment and prevention of parasitic infestations in horses and donkeys due to large and small strongyles, ascarids.
Broadline®
Protects cats against the broadest spectrum of internal and external parasites including adult fleas, flea eggs, flea larvae, ticks, heartworms, hookworms, roundworms, and tapeworms.
Sifrol®
Symptomatic treatment of idiopathic Parkinson’s disease. It may be used as monotherapy or in combination with levodopa. Symptomatic treatment of idiopathic moderate to severe restless legs syndrome.
Actilyse®
Fibrinolytic treatment of acute ischaemic stroke, acute myocardial infarction, acute massive pulmonary embolism. Fibrinolytic treatment of occluded catheters.
Aggrenox®
Prevention of stroke following an initial first stroke, or transient ischaemic attacks (TIA).
Metalyse®
Fibrinolytic treatment of acute myocardial infarction.
Catapresan®
Treatment of hypertension.
Trajenta®
Treatment of type 2 diabetes mellitus to improve glycaemic control in adults, used in monotherapy (if metformin is not tolerated or contraindicated) or in combination therapy.
Jentadueto®
Treatment of type 2 diabetes mellitus to improve glycaemic control in adults when treatment with metformin does not lead to sufficient control or when patients are treated with trajenta® (linagliptin) and metformin.
Jardiance®
Treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise.
Synjardy®
Treatment of type 2 diabetes mellitus to improve glycaemic control in adults when treatment with metformin does not lead to sufficient control or when patients are treated with jardiance® (empagliflozin) and metformin.
Glyxambi®
Treatment of type 2 diabetes mellitus to improve glycaemic control in adults when treatment with both empagliflozin and linagliptin is appropriate (US).
Giotrif®
For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have activating epidermal growth factor receptor (EGFR) mutations. For the treatment of patients with locally advanced or metastatic NSCLC of squamous hist
Vargatef®
Combination therapy with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy.
Lendormin®
Short-term treatment of disorders of initiating and maintaining sleep. Insomnia requiring pharmacological intervention.